Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	4.03B
Revenue (ttm)	1.47B
Net Income (ttm)	170.48M
Shares Out	n/a
EPS (ttm)	0.22
PE Ratio	23.64
Forward PE	n/a
Dividend	0.21 (9.46%)
Ex-Dividend Date	Jul 2, 2024

Volume	165,600
Average Volume	151,100
Open	2.280
Previous Close	2.260
Day's Range	2.240 - 2.310
52-Week Range	1.950 - 2.660
Beta	n/a
RSI	71.38
Earnings Date	Mar 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2023, SGX:T14's revenue was 8.22 billion, a decrease of -0.33% compared to the previous year's 8.25 billion. Earnings were 986.71 million, an increase of 14.49%.

Financial numbers in CNY